Clinical trials: Low Dose
Mycosis Fungoides
Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides
The purpise of this study was to determine the effect of low-dose (4 Gy) total skin electron beam therapy as a second-line treatment of stage IB-II mycosis fungoides.
- Trial name
- NCT00496743
- Testing
- Low-dose total skin electron beam therapy (4 Gy)
- Volunteers
- 10 people
- Sponsor
- Bispebjerg Hospital
Disorder Related to Renal Transplantation, Cytomegalovirus Infections
Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients
There is no consensus on the best immunosuppressive regimen in elderly people. The aim of this study will be to evaluate the efficacy of sirolimus associated with tacrolimus in elderly kidney transplant recipients.
- Trial name
- NCT02683291
- Testing
- sirolimus, tacrolimus, mycophenolate
- Volunteers
- 48 people
- Sponsor
- Associação Médico Espírita de Botucatu
Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
This phase III trial is studying how well combination chemotherapy and radiation therapy work in treating patients with newly diagnosed low-risk rhabdomyosarcoma.
- Conditions
- Adult Rhabdomyosarcoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Previously Untreated Childhood Rhabdomyosarcoma
- Trial name
- NCT00075582
- Testing
- conventional surgery, dactinomycin, cyclophosphamide
- Where
- 163 sites in United States, Australia and 4 more
- Volunteers
- 390 people
- Sponsor
- Children's Oncology Group
Severe Hemophilia A Without Inhibitor, Joint Bleed
Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A
To outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration To study pharmacokinetic, side effect of low dose Emicizumab
- Trial name
- NCT06155955
- Testing
- "Emicizumab", "HEMLIBRA®"
- Where
- Thailand
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
NSCLC, Low Dose Radiotherapy
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
This phase I study aims to investigate the safety and efficacy of whole brain low dose radiotherapy (WB-LDRT) combined with ICI and intrathecal chemotherapy for treatment of refractory meningeal metastasis of lung cancer.
- Conditions
- NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
- Trial name
- NCT06431685
- Testing
- Whole Brain Low Dose Radiotherapy, Pemetrexed, Sintilimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sichuan University
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
This phase II trial studies the side effects and how well low dose ipilimumab works in combination with pembrolizumab in treating patients with melanoma that has spread to the brain.
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT03873818
- Testing
- Ipilimumab, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
ST Elevation (STEMI) Myocardial Infarction of Anterior Wall, Cardiovascular Diseases
Impact, Cost, and Sustainability of a Customized, Low-Cost Intervention to Reduce Cardiovascular Disease Burden in India: A Cluster Randomized Trial
The ICRAG-2 project aims to assess the impact, cost-effectiveness, and sustainability of a low-cost, multipronged intervention package to reduce cardiovascular disease (CVD) burden in India.
- Trial name
- ENABLE (NCT06836661)
- Testing
- FDC and TLC and medication adherance, Patients will Enhanced Usual Care (EUC)
- Where
- India
- Volunteers
- 1,560 people
- Sponsor
- St. John's Research Institute
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480 participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (for example, diabetes and familial…
- Conditions
- Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
- Trial name
- ORION-1 (NCT02597127)
- Testing
- ALN-PCSSC, Normal Saline
- Where
- 54 sites in United States, Canada and 3 more
- Volunteers
- 501 people
- Sponsor
- The Medicines Company
Shoulder Surgery, Nerve Block
The Effects of Dexamethasone on Low Dose Interscalene Brachial Plexus Block
A standard interscalene nerve block is performed with long acting local anesthetic (bupivacaine or ropivacaine in concentrations varying from 0.25% to 0.75%).
- Trial name
- ISB-Dex (NCT02322242)
- Testing
- Systemic Dexamethasone, Perineural dexamethasone
- Where
- Canada
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Dr. Stephen Choi
Acute Myeloid Leukemia
GRASPA Treatment for Patients With Acute Myeloblastic Leukemia
The protocol aims at adding GRASPA (L-asparaginase encapsulated in red blood cells, eryaspase) to standard chemotherapy (low-dose cytarabine) to treat patients older than 65 years diagnosed with AML and unfit for intensive…
- Trial name
- ENFORCE (NCT01810705)
- Testing
- GRASPA
- Where
- 21 sites in France
- Volunteers
- 123 people
- Sponsor
- ERYtech Pharma
COPD
Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
Molecular mechanisms of COPD exacerbations and the modulating effect of low dose theophylline on that inflammation are elucidated in this project.
- Trial name
- NCT00671151
- Testing
- Theophylline
- Where
- Spain
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Son Dureta
Acne Vulgaris
Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser in the Treatment of Acne Erythema
Acne erythema consists of telangiectasia and erythematous papules, without a comedo, which occurs as a result of inflammatory acne.
- Trial name
- NCT05622253
- Testing
- Combined Low-Dose Isotretenion and Long-Pulsed 1064 ND-YAG Laser
- Where
- Egypt
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Zagazig University
Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor
Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
This phase I trial studies the side effects and best dose of activated T-cell therapy when given together with low-dose aldesleukin and sargramostim in treating patients with ovarian, fallopian tube, or primary peritoneal cancer…
- Conditions
- Malignant Ovarian Clear Cell Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02470559
- Testing
- Aldesleukin, HER2Bi-Armed Activated T Cells, Laboratory Biomarker Analysis
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Breast Neoplasms
Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose
For the specific patient population studied receiving 5-Fluorouracil, epirubicin and cyclophosphamide - Docetaxel sequence (cumulative dose <300 mg / m2), using a cryoprotection has never been assessed.
- Trial name
- BANQUISE (NCT02283983)
- Testing
- mittens and booties, cooling helmet
- Where
- 10 sites in France
- Volunteers
- 319 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Systemic Lupus Erythematosus
Anti-infection of Low-does IL-2 in SLE
The objective of this clinical study is to evaluate the potential effect of anti-infection of low-does IL-2 in patients with SLE.
- Trial name
- NCT02932137
- Testing
- Interleukin-2
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Hepatitis C
Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3
This study will examine the effectiveness of low-dose peginterferon and ribavirin therapy for certain patients with chronic hepatitis C-a liver disease that, in some patients, can progress to cirrhosis of the liver, liver cancer…
- Trial name
- NCT00056862
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Alzheimer Disease
Therapeutic Evaluation of Low-dose IL-2-based Immunomodulatory Approach in Patients With Early AD
Study aims at evaluating the therapeutic efficacy and safety of low-dose IL-2 immunomodulatory treatment in patients with early AD, in a phase II, randomized, double blind, placebo-controlled phase II clinical trial.
- Trial name
- IL-2-AD (NCT05468073)
- Testing
- Proleukin
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Centre Hospitalier St Anne
Idiopathic Parkinson's Disease
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons.
- Trial name
- MOTION (NCT01028586)
- Testing
- Safinamide, MAO-B inhibitor
- Where
- Switzerland
- Volunteers
- 507 people
- Sponsor
- Newron Pharmaceuticals SPA
Autism Spectrum Disorder
Use of Low Doses of Interleukin-2 in Autism Spectrum Disorders
Autism spectrum disorders (ASD) are neurodevelopmental disorders that affect around 1% of the population. Matenral immune activation (MIA) during pregnancy is a risk factor for ASD in children (Han 2021), mediated by maternal…
- Trial name
- ALaDIN (NCT07589842)
- Testing
- ILT-101 ld-(IL2), NaCl (0,9%)
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Onychomycosis
Isotretinoin Versus Excimer Light an Adjuvant in Treating Onychomycosis
3 groups of patients with onychomycosis will be recruited. Group A will receive itraconazole alone. Group B will receive itraconazole + low dose isotretinoin and group C will be treated with itraconazole + excimer light sessions.
- Trial name
- NCT06485505
- Testing
- ISOtretinoin 10 MG, excimer light, Itraconazole 200 mg
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Zagazig University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.